Compared to Estimates, Hologic (HOLX) Q1 Earnings: A Look at Key Metrics

For the quarter ended December 2025, Hologic (HOLX) reported revenue of $1.05 billion, up 2.5% over the same period last year. EPS came in at $1.04, compared to $1.03 in the year-ago quarter.The reported revenue represents a surprise of -2.14% over the Zacks Consensus Estimate of $1.07 billion. With the consensus EPS estimate being $1.09, the EPS surprise was -4.46%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Hologic performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenues- GYN surgical: $180.8 million versus the three-analyst average estimate of $180.97 million. The reported number represents a year-over-year change of +8.7%.Revenues- Diagnostics- Molecular diagnostics: $329.2 million versus the three-analyst average estimate of $354.66 million. The reported number represents a year-over-year change of -3.5%.Revenues- Diagnostics- Blood screening: $8.4 million versus $4.77 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +104.9% change.Revenues- Breast health- Breast imaging: $280 million versus $294.22 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -0.6% change.Revenues- Total Diagnostics: $464.4 million compared to the $479.84 million average estimate based on three analysts. The reported number represents a change of -1.3% year over year.Revenues- Skeletal health: $26.7 million compared to the $20.13 million average estimate based on three analysts. The reported number represents a change of +69% year over year.Revenues- Diagnostics- Cytology and perinatal: $126.8 million versus $120.41 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +1.1% change.Revenues- Total Breast health: $375.9 million versus $392.22 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +1.8% change.Revenues- Breast health- Interventional breast solutions: $95.9 million versus the three-analyst average estimate of $98 million. The reported number represents a year-over-year change of +9.6%.Revenues- Service and other: $216.4 million versus $212.72 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +6.1% change.Revenues- Product: $831.4 million versus the two-analyst average estimate of $860.93 million. The reported number represents a year-over-year change of +1.7%.View all Key Company Metrics for Hologic here>>>Shares of Hologic have returned +0.8% over the past month versus the Zacks S&P 500 composite's +0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.SeeWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks